CN115715198A - 新型的基于沙门氏菌的冠状病毒疫苗 - Google Patents

新型的基于沙门氏菌的冠状病毒疫苗 Download PDF

Info

Publication number
CN115715198A
CN115715198A CN202180024934.7A CN202180024934A CN115715198A CN 115715198 A CN115715198 A CN 115715198A CN 202180024934 A CN202180024934 A CN 202180024934A CN 115715198 A CN115715198 A CN 115715198A
Authority
CN
China
Prior art keywords
protein
cov
sars
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180024934.7A
Other languages
English (en)
Chinese (zh)
Inventor
海因茨·卢本奥
马克·曼苏尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nec Orkmnet
Original Assignee
Nec Orkmnet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nec Orkmnet filed Critical Nec Orkmnet
Publication of CN115715198A publication Critical patent/CN115715198A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180024934.7A 2020-03-31 2021-03-31 新型的基于沙门氏菌的冠状病毒疫苗 Pending CN115715198A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20167405 2020-03-31
EP20167405.8 2020-03-31
PCT/EP2021/058513 WO2021198376A1 (en) 2020-03-31 2021-03-31 Novel salmonella-based coronavirus vaccine

Publications (1)

Publication Number Publication Date
CN115715198A true CN115715198A (zh) 2023-02-24

Family

ID=70110247

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024934.7A Pending CN115715198A (zh) 2020-03-31 2021-03-31 新型的基于沙门氏菌的冠状病毒疫苗

Country Status (8)

Country Link
US (1) US20230137174A1 (https=)
EP (1) EP4126022A1 (https=)
JP (1) JP2023519562A (https=)
KR (1) KR20220161444A (https=)
CN (1) CN115715198A (https=)
AU (1) AU2021250442A1 (https=)
CA (1) CA3170674A1 (https=)
WO (1) WO2021198376A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39378A (es) * 2020-08-14 2022-01-31 Univ Wuerzburg J Maximilians Vacuna de salmonella para el tratamiento de coronavirus
CN114517205A (zh) * 2020-11-20 2022-05-20 北京震旦鼎泰生物科技有限公司 融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084583A2 (en) * 2006-01-19 2007-07-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Soluble fragments of the sars-cov spike glycoprotein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030122A2 (en) * 2003-08-13 2005-04-07 Chiron Corporation Inactivated host cell delivery of polynucleotides encoding immunogens
CN1327900C (zh) * 2005-03-30 2007-07-25 武汉大学 一种染色体上携带病毒基因的减毒伤寒杆菌疫苗及制备方法
CA2853656C (en) 2011-12-22 2020-12-29 Vaximm Ag Method of producing high yield attenuated salmonella strains
CA3063419A1 (en) * 2017-05-15 2018-11-22 University Of Maryland, Baltimore Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
WO2020237246A1 (en) * 2019-05-23 2020-11-26 University Of Maryland, Baltimore Live attenuated non-transmissible vaccines
US10973908B1 (en) * 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084583A2 (en) * 2006-01-19 2007-07-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Soluble fragments of the sars-cov spike glycoprotein

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GALEN JE等: "Salmonella enterica serovar Typhi live vector vaccines finally come of age", IMMUNOL CELL BIOL, vol. 87, no. 5, 5 May 2009 (2009-05-05), pages 2 *
KIRCHDOERFER RN等: "Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis", SCI REP, vol. 8, no. 1, 24 October 2018 (2018-10-24), pages 2 *
LUO F等: "Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination", CLIN VACCINE IMMUNOL, vol. 14, no. 8, 27 June 2007 (2007-06-27) *
OU X等: "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV", NAT COMMUN, vol. 11, no. 1, 27 March 2020 (2020-03-27) *
WOO PC等: "SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus", VACCINE, vol. 23, no. 42, 13 June 2005 (2005-06-13) *
WU F等: "A new coronavirus associated with human respiratory disease in China", NATURE, vol. 579, no. 7798, 3 February 2020 (2020-02-03), pages 266 *

Also Published As

Publication number Publication date
CA3170674A1 (en) 2021-10-07
AU2021250442A1 (en) 2022-11-10
US20230137174A1 (en) 2023-05-04
WO2021198376A1 (en) 2021-10-07
JP2023519562A (ja) 2023-05-11
KR20220161444A (ko) 2022-12-06
EP4126022A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
CN111939250B (zh) 一种预防covid-19的疫苗及其制备方法
AU2017297610B2 (en) Compositions and methods for alphavirus vaccination
JP7457733B2 (ja) 改変アデノウイルス
CN106999565B (zh) 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗
JP5123343B2 (ja) Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
CN109843323B (zh) 用于黄病毒疫苗接种的组合物和方法
US20220265812A1 (en) Hiv antigens and mhc complexes
CN110430893A (zh) 用于癌症免疫疗法的新型的靶向pd-l1的dna疫苗
KR20250071877A (ko) Sars-cov-2 면역원성 조성물
CN115715198A (zh) 新型的基于沙门氏菌的冠状病毒疫苗
US20230158133A1 (en) Wt1 targeting dna vaccine for combination therapy
AU2019334131B2 (en) Neoantigen targeting DNA vaccine for combination therapy
EP3600399A1 (en) Methods and compositions for vaccinating against malaria
CN115335390A (zh) 基于SARS-CoV-2的S蛋白的疫苗和组合物
US20240350607A1 (en) Tuberculosis vaccines
IL295546A (en) Neoantigens expressed in ovarian cancer and their uses
CA3009928C (en) Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
CN103965288B (zh) 登革病毒特异性hla-a*2402限制性表位肽及应用
Steele Processing and presentation of a Chlamydia trachomatis antigen to CD8+ T cells
EA039715B1 (ru) Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination